

**OZEM**

**GLP-1 & Weight Loss ETF**

Investment Case December 2024



Investors should consider the investment objectives, risk, charges and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about The Roundhill GLP-1 & Weight Loss ETF please call 1-877-220-7649 or visit the website at [roundhillinvestments.com/etf/OZEM](https://roundhillinvestments.com/etf/OZEM).

Read the prospectus or summary prospectus carefully before investing.



# Table of Contents

## **GLP-1 Overview**

### **Market Opportunity**

- Obesity Epidemic
- Revolutionary Drugs
- Market Growth

### **Introducing OZEM**

# GLP-1 Overview


## What are GLP-1 Drugs?

GLP-1 receptor agonists represent a transformative advancement in the fight against obesity, a growing global health crisis. These medications function by mimicking the activity of the naturally occurring hormone GLP-1, which helps regulate blood sugar and decrease appetite. The efficacy of GLP-1 treatments in promoting **significant weight loss** and improving metabolic health.

## The GLP-1 Opportunity

The opportunity in the GLP-1 weight loss market is fueled by **rising obesity rates** worldwide and the inadequacy of traditional weight management strategies, which often yield minimal and unsustainable results. As obesity continues to be linked with various health complications such as diabetes, cardiovascular disease, and certain cancers, the demand for effective pharmacological interventions like GLP-1 receptor agonists is expected to surge.

The Fund may hold one or more of the companies or products displayed.






# Market Opportunity: **Obesity Epidemic**

Rising obesity rates worldwide are straining healthcare systems economically. According to the WHO, global obesity rates have nearly tripled since 1975 and are projected to impact over **half the global population by 2035**, compared to 38% in 2020.

The United States continues to face a severe obesity epidemic that has significantly worsened over the past several decades.

In the U.S., obesity prevalence among adults increased from 30.5% to **41.9%** over the twenty years ending 2020, and severe obesity rates doubled during the same period.

### U.S. Obesity Rate



For informational purposes only. Not meant to represent the Fund. Forecasts are inherently limited and cannot be relied upon. Actual results may vary.


Source: WHO, Global Health Observatory (2022), Ourworldindata.com. Estimated prevalence of obesity, based on general population surveys and statistical modeling. Obesity is a risk factor for chronic complications, including cardiovascular disease, and premature death.

# Market Opportunity: Revolutionary Drugs

GLP-1 treatments are at the cutting-edge of medical advancements in weight management. These treatments have shown transformative effects on weight loss and metabolic health, with drugs like **Ozempic, Wegovy, Zepbound, and Mounjaro** leading the charge. Wegovy, specifically, has been shown to help patients achieve an average weight loss of about **15%** of their body weight over 68 weeks.

Beyond weight management, GLP-1 receptor agonists are being explored for potential uses in other serious health conditions. Emerging research suggests that these drugs could also play a significant role in managing type 2 diabetes, non-alcoholic steatohepatitis (NASH), cardiovascular diseases, and even addiction.

## Weight Loss Efficacy



For informational purposes only. Not meant to represent the Fund. Forecasts are inherently limited and cannot be relied upon. Actual results may vary.

The Fund may hold one or more of the companies or products displayed.

Source: Stifel, healthcare, "Obesity drug review", market update July 1st, 2023. Note: chart shows Placebo Adjusted Weight Loss Among Obese Persons by Therapeutic Approach (48 Weeks, Highest Dose Used).




## Market Opportunity: **Market Growth**

The obesity treatment market is set for explosive growth. Goldman Sachs Research forecasts that by 2030, the market could reach **\$130 billion.**<sup>1</sup>

This growth is driven by increasing global obesity rates, which are expected to impact **one in four people by 2035.**

### Global Chronic Weight Management Market Growth



For informational purposes only. Not meant to represent the Fund. Forecasts are inherently limited and cannot be relied upon. Actual results may vary.

<sup>1</sup>Source: Goldman Sachs Global Investment Research; Company data. Obesity Market Model update (5/30/2024).



# Introducing **OZEM**: The GLP-1 & Weight Loss ETF

## 3 Reasons to consider OZEM ETF:




### Obesity Epidemic

Global obesity rates have nearly tripled since 1975 and are projected to impact over half the population by 2035.



### Revolutionary Drugs

Groundbreaking GLP-1 treatments, such as Ozempic, Wegovy, and Zepbound, are leading medical advancements in weight management.



### Market Growth

Goldman Sachs Research forecasts that the obesity treatment market could reach \$130 billion by 2030.

Ticker	Primary Exchange	Inception Date	Expense Ratio	CUSIP
OZEM	Nasdaq	05/21/2024	0.59%	77926X882





# OZEM — Roundhill GLP-1 & Weight Loss ETF

Investors should consider the investment objectives, risk, charges and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about Roundhill ETFs please call 1-855-561-5728 or visit the website at [www.roundhillinvestments.com/etf/OZEM](http://www.roundhillinvestments.com/etf/OZEM). Read the prospectus or summary prospectus carefully before investing.

**Health Care Companies Risk.** Health care companies, such as companies providing medical and healthcare goods and services, companies engaged in manufacturing medical equipment, supplies and pharmaceuticals, as well as operating health care facilities and the provision of managed health care, may be affected by government regulations and government health care programs, increases or decreases in the cost of medical products and services and product liability claims, among other factors. Many health care companies are heavily dependent on patent protection, and the expiration of a company's patent may adversely affect that company's profitability. Health care companies are also subject to competitive forces that may result in price discounting, may be thinly capitalized and susceptible to product obsolescence.

**Pharmaceutical Companies Risk.** The Fund may have significant exposure to pharmaceutical companies in connection with its investments in GLP-1 & Weight Loss Companies. Pharmaceuticals companies may be affected by industry competition, dependency on a limited number of products, obsolescence of products, government approvals and regulations, loss or impairment of intellectual property rights and litigation regarding product liability. Pharmaceutical are subject to competitive forces that may make it difficult to raise prices of their products and may result in price discounting. The profitability of some pharmaceuticals companies may be dependent on a relatively limited number of products. The research and development costs required to bring a new product to market are substantial with no guarantee that the product will ever become profitable. Many new products are subject to gaining the approval of the U.S. Food and Drug Administration ("FDA"), which can be long and costly. Many pharmaceutical companies are heavily dependent on patents and intellectual property rights. The loss or impairment of these rights may adversely affect the profitability of these companies. Pharmaceuticals companies may also be subject to extensive litigation based on product liability and similar claims.

**Biotechnology Companies Risk.** The Fund may have significant exposure to biotechnology companies in connection with its investments in GLP-1 & Weight Loss Companies. Biotechnology companies invest heavily in research and development which may not necessarily lead to commercially successful products. Biotechnology companies are subject to increased governmental regulation which may delay or inhibit the release of new products. The effects of high development costs and increased regulation may be exacerbated by a company's inability to raise prices to cover costs because of managed care pressure or price controls. Many biotechnology companies are dependent upon their ability to use and enforce intellectual property rights and patents. Any impairment of such rights may have adverse financial consequences. Biotechnology stocks, especially those issued by smaller, less-seasoned companies, tend to be more volatile than the overall market. Biotechnology companies can also be significantly affected by technological change and obsolescence, product liability lawsuits and consequential high insurance costs.

**Concentration Risk.** The Fund is concentrated in the industry or group of industries comprising the health care sector. The Fund may be susceptible to an increased risk of loss, including losses due to adverse events that affect the Fund's investments more than the market as a whole, to the extent that the Fund's investments are concentrated in the securities and/or other assets of a particular issuer or issuers, country, group of countries, region, market, industry, group of industries, sector, market segment or asset class.

**New Fund Risk.** The Fund is a recently organized investment company with a limited operating history. As a result, prospective investors have a limited track record or history on which to base their investment decision.

Roundhill Financial Inc. serves as the investment advisor. The Funds are distributed by Foreside Fund Services, LLC which is not affiliated with Roundhill Financial Inc., U.S. Bank, or any of their affiliates.